TAILORED TOOLKIT

Capacity strengthening toolkit providing participants with practical tools with which to implement hepatitis C testing and treating processes in their setting.
ASHM     Australia     Australia

INHSU has collaborated with the Australasian Society for HIV, Viral
Hepatitis and Sexual Health Medicine (ASHM) and the Kirby Institute at
the University of New South Wales (UNSW) to develop and deliver
hepatitis C education, globally.

The Hepatitis C in Primary Care and Drug and Alcohol Settings Education Program provides healthcare practitioners with the knowledge and skills to expand hepatitis C (HCV) care beyond hospital settings.

WHERE IS IT TAKING PLACE?

WHY IS IT IMPORTANT?

Globally, HCV-related morbidity and mortality are rising due to large populations with chronic infection, an ageing infected population and low treatment uptake.

However, following the advent of well-tolerated, simple, short-course direct acting antiviral (DAA) interferon-free HCV treatment regimens with cure rates >95%, there is potential to reverse the rising burden of disease with increased treatment. By expanding HCV care into primary care and drug and alcohol settings we have an opportunity to enhance HCV assessment, management and treatment, particularly among people who use drugs.

WHO SHOULD TAKE PART?

The Program is designed for healthcare practitioners working in primary care or drug and alcohol settings or working with people who use drugs.

The Program is tailored for each country in close collaboration with local stakeholders to ensure education materials and resources are in-line with local guidelines and appropriately support increased HCV screening, linkage-to-care and treatment for people living with HCV.

If you are interested in access the Education Program but do not see your country listed, please contact info@inhsu.org.

INTERNATIONAL EDUCATION STEERING COMMITTEE

The Education Program is developed and delivered in collaboration with many partners. The International Education Program Steering Committee provide oversight and direction to the Program and we thank them for their involvement.

  Prof. Jason GrebelySenior Research Fellow / President | Viral Hepatitis Clinical Research Program, The Kirby Institute / International Network on Hepatitis in Substance Users | Australia

  Ms. Emma Day | Program Manager | Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine | Australia

  Dr. Alessio Aghemo | Professor of Gastroenterology | Humanitas University | Italy

  Prof. John Dillon | Professor of Hepatology and Gastroenterology | Ninewells Hospital, University of Dundee | UK

  Prof. Karine Lacombe | Professor | Infectious and Tropical Diseases Department, Saint-Antoine Hospital  France

  Prof. Jeffrey V. Lazarus | Associate Professor / Associate Researcher | University of Barcelona / ISGlobal, Hospital Clinic, University of Barcelona | Spain

  Prof. Rui Tato Marinho | Gastroenterology Physician | Hospital Santa Maria | Portugal

  Dr. Alberto Moriggia | MD, Infectious Disease Specialist | Epatocentro Liver Clinic and Ingrado Addiction Clinic | Switzerland

  Dr. Anne Øvrehus | Staff specialist, Infectious Diseases | Department of Infectious Diseases, Odense University Hospital | Denmark

  Prof. Jens Reimer | Professor of Psychiatry | University Medical Center Hamburg | Germany

  Dr. Hemant Shah | Hepatologist & Education Director | University Health Network & Toronto Centre for Liver Disease  | Canada

  Prof. Marta Torrens | Addiction Specialist  | Hospital del Mar, Barcelona | Spain